HRTX
Heron Therapeuti
0.3843$
+15.9%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +8.9% | +1.3% | +3.9% | -8.9% | +24.3% | -4.6% | -4.4% | +2.7% | +6.2% | -14.5% | +8.5% | – | |
| – | -45.7% | -14.6% | +24.6% | -10.1% | +8.1% | -17.3% | +16.6% | +56.1% | -50.3% | +39.1% | +8.8% | – | |
| – | +84.1% | +7.7% | -2.7% | -8.4% | +30.8% | -0.4% | -10.2% | -16.5% | +44.3% | -26.9% | +8.4% | – | |
| – | -19.2% | -57.9% | -3.8% | +0.7% | -28.8% | -28.3% | +28.7% | +18.3% | +8.0% | -36.3% | +13.3% | – | |
| – | -3.0% | +32.6% | -7.1% | -11.0% | -1.8% | +4.6% | +13.9% | -3.4% | -3.8% | -9.7% | -7.2% | – | |
| – | -9.4% | -10.3% | +3.0% | -13.0% | -5.1% | +3.5% | +6.2% | -7.1% | +22.2% | -12.3% | -2.4% | – | |
| – | – | – | – | – | – | -24.4% | -151.9% | – | – | -12,639.5% | – | – | |
| – | +285.1% | -74.0% | -29.0% | +25.0% | +786.4% | -88.7% | +0.0% | +480.0% | -65.5% | – | – | – | |
| – | – | – | – | – | – | -28.1% | -190.4% | – | – | – | – | – | |
| – | -61.5% | +118.9% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | -28.1% | -190.4% | – | – | – | – | – | |
| – | – | – | – | – | – | -57.8% | -148.0% | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.